Among 1640 patients who initiated biologic therapy, 7.0% had low BSA involvement, 46.9% had medium BSA, and 46.2% had high BSA. Despite these differences in skin involvement, PROs showed ...

Patients with psoriasis who had low body surface area (BSA) involvement experienced similarly poor QOL and symptom burden compared to patients with higher BSA.

Various approaches to estimating body surface area (BSA) offer simpler means to determine disease severity. The AAD/NPF ...

A new consensus statement endorsed by the National Psoriasis Foundation formally defined on-treatment remission for plaque ...

Assessment of the BSA affected by psoriasis informs diagnosis and treatment; however, physician estimates of affected BSA vary. Physician assessments of BSA tended to exceed those of the computer ...

The AAD/NPF guidelines define mild psoriasis as <3% BSA and moderate at 3-10%. "You have to document BSA if the patient goes on a biologic agent," said Oyetewa Asempa, MD, of Baylor College of ...

A new consensus from the National Psoriasis Foundation outlines a clear benchmark for remission to improve treatment decisions and patient outcomes.

To determine the risk of T2DM, researchers compared adults with psoriasis (n=8124), grouping them by affected BSA, to those without psoriasis (n=76,599); patients were followed for ~4 years.

NEW ORLEANS — Apremilast 30 mg significantly improved genital psoriasis severity and quality of life compared with placebo in the first trial to study an oral treatment for this indication ...

They found patients with a BSA of two percent or less had a relative risk of 1.21 for developing diabetes, meaning their risk is 21 percent higher than those without psoriasis.

They found patients with a BSA of two percent or less had a relative risk of 1.21 for developing diabetes, meaning their risk is 21 percent higher than those without psoriasis.